Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genetic Services Laboratory, |
RCV000116944 | SCV000151053 | uncertain significance | not provided | 2013-10-24 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000116944 | SCV000240965 | uncertain significance | not provided | 2015-12-28 | criteria provided, single submitter | clinical testing | The I462T variant has not been published as a pathogenic variant, nor has it been reported as a benign polymorphism to our knowledge. It was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. The I462T variant is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. This substitution occurs at a position that is conserved across species. However, missense variants in nearby residues have not been reported in the Human Gene Mutation Database in association with EFHC1-related disorders (Stenson et al., 2014). In silico analysis is inconsistent in its predictions as to whether or not the variant is damaging to the protein structure/function. |
Fulgent Genetics, |
RCV000515423 | SCV000611475 | uncertain significance | Absence seizure; Juvenile myoclonic epilepsy | 2017-05-23 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003764815 | SCV000640920 | likely benign | Absence seizure; Myoclonic epilepsy, juvenile, susceptibility to, 1 | 2024-07-08 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004019629 | SCV003879605 | uncertain significance | not specified | 2023-02-22 | criteria provided, single submitter | clinical testing | The c.1385T>C (p.I462T) alteration is located in exon 8 (coding exon 8) of the EFHC1 gene. This alteration results from a T to C substitution at nucleotide position 1385, causing the isoleucine (I) at amino acid position 462 to be replaced by a threonine (T). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |